A Randomized, Open Label, Multicenter, Phase II, 2-Arm Study comparing the conventional 3 weekly schedule of Jevtana (Cabazitaxel) with a weekly regimen in patients with Metastastic Castration Resistant Prostate Cancer ConWeCab.
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2015
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms ConCab
- 10 Jun 2017 Biomarkers information updated
- 30 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Apr 2015 Planned End Date changed from 1 Oct 2015 to 1 Apr 2016 according to ClinicalTrials.gov.